Value in Health Regional Issues

Slides:

Advertisements

Similar presentations

Value in Health Regional Issues

Advertisements

Volume 14, Issue 1, Pages (January 2011)

Volume 15, Issue 1, Pages S20-S28 (January 2012)

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia Juan-Carlos Castro, MD,

Volume 15, Issue 2, Pages (March 2012)

Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Klára Kruntorádová, MSc, Jiří Klimeš,

Volume 14, Issue 8, Pages (December 2011)

Volume 17, Issue 2, Pages (March 2014)

Value in Health Regional Issues

Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico Kely Rely, Rosa María.

The Health Economic Impact of Universal Infant Vaccination with the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine.

Value in Health Regional Issues

Value in Health Regional Issues

The Development of the Romanian Scorecard HTA System

Using Dynamic Transmission Modeling to Determine Vaccination Coverage Rate Based on 5-Year Economic Burden of Infectious Disease: An Example of Pneumococcal.

Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.

Value in Health Regional Issues

Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt

Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future? Emmanuel Ankrah Odame, MBCHB, MPH Value in.

The Cost-Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for Females in Japan Kaoru Yamabe, MSc, Puneet K. Singhal,

Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost- Effectiveness Affordability Curves in Health Care Decision Making

Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in Brazil Ronaldo K.

Value in Health Regional Issues

Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico Kely Rely, Rosa María.

Boxiong Tang, MD, PhD, Eran Harary, MD, Ricky Kurzman, MSc, Joaquín F

Ernest Attuquaye Quaye, BPharm, MPH, Edward O

Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Klára Kruntorádová, MSc, Jiří Klimeš,

Value in Health Regional Issues

Value in Health Regional Issues

Rutger Daems, PhD, Edith Maes, DBA, Christoph Glaetzer, Dipl, Kfm

Cost-Effectiveness Analysis of a Screening Program for Breast Cancer in Vietnam Lan Hoang Nguyen, Wongsa Laohasiriwong, John Frederick Stewart, Pamela.

Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,

Value in Health Regional Issues

Value in Health Regional Issues

Value in Health Regional Issues

Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore Vivianne Shih, PharmD, BCOP, BCPS, Alexandre Chan, PharmD,

Assessment of Adverse Events and Quality of Life of Cancer Patients in a Secondary Level Care, Rural Hospital in South India S.K.R. Sowmya, PharmD, Dixon.

Cost Effectiveness of Dulaglutide Compared with Liraglutide and Glargine in Type 2 Diabetes Mellitus Patients in Colombia Pieralessandro Lasalvia, Laura.

Assessment of Effect of Diabetes on Health-Related Quality of Life in Patients with Coronary Artery Disease Using the EQ-5D Questionnaire Bhavik Shah,

Jinhyun Kim, PhD, Eunhee Lee, PhD, Sungjae Kim, PhD, Tae Jin Lee, PhD

Cost-Effectiveness of Screening and Treatment for Cervical Cancer in Tanzania: Implications for other Sub-Saharan African Countries Stephanie Nelson,

Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia

Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD

Omneya Mohamed, PhD, David H. Kreling, PhD

Patient Utility Measurement for Managing Ureteral Stones: A Modified Standard Gamble Approach Ching-Yuan Fann, PhD, Po-Chien Huang, MD, MS, Amy Ming-Fang.

Value in Health Regional Issues

Burden of Disease Studies in the Asia-Pacific Region: Are There Enough being Performed to Provide Information for Evidence-Based Health Policy? Fei-Li.

Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.

Transforming Public Servants’ Health Care Organization in Greece through the Implementation of an Electronic Referral Project Kyriakos Souliotis, PhD,

Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective Bruno Salgado Riveros,

Generalized Cost-Effectiveness Analysis of Pharmaceutical Interventions for Primary Prevention of Cardiovascular Disease in Thailand Panrasri Khonputsa,

Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes Maxwell O. Adibe,

Reconciling Cancer Care Costs Reported by Different Government Agencies in Taiwan: Why Costing Approach Matters? Chun-Ru Chien, MD, PhD, Ya-Chen Tina.

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia Juan-Carlos Castro, MD,

Economic Evaluation of Pravastatin for Primary Prevention of Coronary Artery Disease Based on Risk Prediction from JALS-ECC in Japan Yoshie Onishi, MS,

The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System Juan Guillermo Ariza, MD, MSc, Per-Olof Thuresson,

Use of the EQ-5D Instrument and Value Scale in Comparing Health States of Patients in Four Health Care Programs among Health Care Providers Valentina.

Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD

Value in Health Regional Issues

Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea Ji Haeng Heo, MS, Karen L.

Dossier System as a Practical Tool for Compiling Reimbursement Lists

Concept of Combining Cost-Effectiveness Analysis and Budget Impact Analysis in Health Care Decision-Making Roza Ismailovna Yagudina, PhD, Andrey Urievich.

Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not.

Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico

Social Cost of Substance Abuse in Russia

Anut Sakulsupsiri, MSc, Phantipa Sakthong, PhD, Win Winit-Watjana, PhD

A Comparison of 1-Year Treatment Costs in Patients with Type 2 Diabetes Following Initiation of Insulin Glargine or Insulin Detemir in Argentina Joaquín.

Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational.

Cost-Effectiveness of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov.

Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD

Presentation transcript:

Value in Health Regional Issues Cost-Utility Analysis of Human Papillomavirus Vaccination and Cervical Screening on Cervical Cancer Patient in Indonesia Didik Setiawan, MSc, Apt, Franklin Christiaan Dolk, MSc, Auliya A. Suwantika, PhD, Tjalke Arend Westra, PhD, Jan C. WIlschut, PhD, Maarten Jacobus Postma, PhD Value in Health Regional Issues Volume 9, Pages 84-92 (May 2016) DOI: 10.1016/j.vhri.2015.10.010 Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 Markov model for the development of cervical cancer. Value in Health Regional Issues 2016 9, 84-92DOI: (10.1016/j.vhri.2015.10.010) Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 2 Estimated annual cases of cervical cancer prevented (A) and life-years saved (B) by VIA screening, or VIA screening in combination with HPV vaccination. HPV, human papillomavirus; VIA, visual inspection with acetic acid. Value in Health Regional Issues 2016 9, 84-92DOI: (10.1016/j.vhri.2015.10.010) Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 3 The effect of market vaccine price on ICER in terms of booster dose is needed (black square) and not needed (gray square) to achieve lifelong protection. ICER, incremental cost-effectiveness ratio; I$, international dollar. Value in Health Regional Issues 2016 9, 84-92DOI: (10.1016/j.vhri.2015.10.010) Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 4 Cost-effectiveness acceptability curve, specifically 1 to 3 times the gross domestic product per capita is indicated with the corresponding probability to be cost-effective. HPV, human papillomavirus; I$, international dollar; QALY, quality-adjusted life-year; VIA, visual inspection with acetic acid. Value in Health Regional Issues 2016 9, 84-92DOI: (10.1016/j.vhri.2015.10.010) Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 5 Univariate sensitivity analyses for VIA screening alone (A) and VIA screening combined with vaccination (B) compared with no intervention. CC, cervical cancer; QALY, quality-adjusted life-year; VIA, visual inspection with acetic acid. Value in Health Regional Issues 2016 9, 84-92DOI: (10.1016/j.vhri.2015.10.010) Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions